Longevity biotech NewLimit raised $435 million in a Series C to fund its first human trial of a cell age reprogramming therapy, after faster-than-expected scientific progress. The company says it identified a lead liver candidate by the end of last year and now plans to initiate Phase 1 trials next year, with fatty liver disease as an initial enrollment focus. NewLimit’s platform uses combinations of transcription factors delivered in mRNA lipid nanoparticles to reset organ biological age, aiming to improve regenerative capacity and resilience under stress in preclinical models. The round size and rapid progression from earlier fundraising rounds reinforce confidence in translational readiness. For the longevity sector, the move signals that cell-state reprogramming is attracting late-stage institutional capital, potentially accelerating the shift from discovery-stage claims to clinical validation.